A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

NCT05159908 PHASE2 COMPLETED

This study will evaluate the safety, pharmacokinetics, and efficacy of three different doses of NBI-921352 versus placebo in adults with focal onset seizures

Details

Lead sponsor	Neurocrine Biosciences
Phase	PHASE2
Status	COMPLETED
Enrolment	101
Start date	Mon Nov 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Aug 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Focal Onset Seizure
• Focal Onset Epilepsy

Interventions

• NBI-921352
• Placebo

Countries

France, Italy, Belgium, Hungary, Australia, Spain, Czechia